These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 26235372)

  • 1. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
    Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
    Tomczyk S; Lynfield R; Schaffner W; Reingold A; Miller L; Petit S; Holtzman C; Zansky SM; Thomas A; Baumbach J; Harrison LH; Farley MM; Beall B; McGee L; Gierke R; Pondo T; Kim L
    Clin Infect Dis; 2016 May; 62(9):1119-25. PubMed ID: 26908787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
    Hsu KK; Shea KM; Stevenson AE; Pelton SI;
    Pediatr Infect Dis J; 2010 Apr; 29(4):289-93. PubMed ID: 19935447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the Seven-valent Pneumococcal Conjugate Vaccine on Acute Otitis Media in Japanese Children: Emergence of Serotype 15A Multidrug-resistant Streptococcus pneumoniae in Middle Ear Fluid Isolates.
    Ozawa D; Yano H; Endo S; Hidaka H; Kakuta R; Okitsu N; Kanamori H; Ogawa M; Ichimura S; Shimojima M; Inomata S; Kaku M; Katori Y
    Pediatr Infect Dis J; 2015 Sep; 34(9):e217-21. PubMed ID: 26083590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods.
    Yildirim I; Stevenson A; Hsu KK; Pelton SI
    Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH; Martin I; Griffith A; Lefebvre B; McGeer A; Lovgren M; Tyrrell GJ; Desai S; Sherrard L; Adam H; Gilmour M; Zhanel GG; ;
    Can J Microbiol; 2013 Dec; 59(12):778-88. PubMed ID: 24313450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015.
    Kaur R; Casey JR; Pichichero ME
    Pediatr Infect Dis J; 2016 Aug; 35(8):901-6. PubMed ID: 27420806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.